What is the appropriate dosing, titration, and monitoring for selegiline in an adult over 60 with early-stage Parkinson’s disease?

Selegiline Dosing and Management in Early Parkinson's Disease (Age >60)

Start selegiline at 5 mg twice daily (morning and lunch) for a total of 10 mg/day, and do not exceed this dose due to loss of MAO-B selectivity and increased risk of hypertensive crisis at higher doses 1.

Initial Dosing and Titration

The FDA-approved regimen is straightforward:

• Start immediately at 5 mg twice daily (breakfast and lunch) 1
• Total daily dose: 10 mg/day - this is both the starting and maintenance dose
• No gradual titration is required for most patients, though some protocols use 2.5 mg increments over 2 weeks if tolerability is a concern 2

The twice-daily split dosing (rather than once daily) helps minimize insomnia, which can occur if the drug is taken later in the day due to its amphetamine metabolites 1.

Critical Dose Ceiling

Never exceed 10 mg/day 1. At doses above 10 mg/day, selegiline loses its MAO-B selectivity and begins inhibiting MAO-A, which creates serious risks:

• Loss of protection against tyramine-containing foods (cheese, wine, aged meats)
• Risk of hypertensive crisis
• The threshold for non-selective MAO inhibition may be as low as 30-40 mg/day, but selectivity diminishes progressively above 10 mg 1

Even at the recommended 10 mg/day dose, rare hypertensive reactions with tyramine-containing foods have been reported 1.

Levodopa Dose Adjustment

After 2-3 days of selegiline treatment, attempt to reduce levodopa/carbidopa by 10-30% 1. This reduction:

• Was achieved in typical trial participants
• Helps prevent dyskinesias from excessive dopaminergic stimulation
• Can be further reduced during continued therapy as tolerated

The mechanism is that selegiline blocks dopamine catabolism via MAO-B inhibition and also blocks dopamine reuptake, effectively amplifying levodopa's effects 1.

Monitoring Requirements

Drug Interactions - Critical Contraindications

Absolutely avoid these combinations 1:

• Tricyclic antidepressants (amitriptyline, protriptyline): Risk of severe CNS toxicity, hyperpyrexia, death
• SSRIs (fluoxetine, sertraline, paroxetine): Risk of serotonin syndrome with hyperthermia, rigidity, autonomic instability, mental status changes progressing to coma
• Sympathomimetics (ephedrine, pseudoephedrine): Risk of hypertensive crisis

Washout periods required:

• Stop selegiline 14 days before starting tricyclics or SSRIs
• Stop fluoxetine at least 5 weeks before starting selegiline (due to long half-life of fluoxetine and active metabolites) 1

Adverse Events to Monitor

The most common adverse events requiring monitoring include 3:

• Neuropsychiatric symptoms (31.6% vs 26.7% placebo): agitation, confusion, hallucinations 4
• Dyskinesias - may worsen initially due to enhanced dopaminergic effect
• Insomnia - due to amphetamine metabolites
• Orthostatic hypotension
• Nausea/vomiting
• Increased "off" time initially (usually resolves after dose adjustments)

Efficacy Monitoring

Monitor UPDRS scores over time. Evidence shows progressive improvement with longer treatment duration 4:

• 1 month: -3.56 point reduction
• 3 months: -3.32 points
• 6 months: -7.46 points
• 12 months: -5.07 points
• Long-term (48-60 months): -8.78 to -11.06 points

This suggests the drug provides sustained and potentially increasing benefit over years of treatment.

Special Considerations for Age >60

While the evidence base for selegiline in early PD is strong, note that most high-quality trials (like EarlyStim) specifically enrolled patients under age 60 5. For patients over 60:

• Age itself is a relative contraindication for invasive therapies like DBS, but not for oral medications like selegiline
• Increased vigilance for neuropsychiatric adverse events is warranted
• Comorbidities and polypharmacy increase risk of drug interactions
• Carefully screen medication lists for contraindicated drugs before initiating

Pharmacokinetic Considerations

• Bioavailability: Only 10% (extensive first-pass metabolism) 6
• Peak levels: Achieved in under 1 hour 6
• Half-life: ~1.5 hours for parent compound, but MAO-B inhibition lasts much longer (86% inhibition within 2-4 hours, takes 2 weeks to return to baseline) 6
• Food effect: 3-fold increase in drug exposure with food 6
• Metabolites: Converted to desmethylselegiline, levoamphetamine, and levomethamphetamine 1, 6

Evidence Quality Note

The recommendation for 10 mg/day dosing is based on FDA labeling 1 and supported by multiple RCTs including the landmark DATATOP trial 7. Research suggests lower doses (2.5-5 mg/day) may achieve >95% MAO-B inhibition 8, 9, but clinical trials establishing efficacy used 10 mg/day, and this remains the evidence-based standard dose.